• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/3/21 1:13:21 PM ET
    $SNN
    Industrial Specialties
    Health Care
    Get the next $SNN alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2 )*

                

    SMITH & NEPHEW PLC


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    G82343164


    (CUSIP Number)

    December 31, 2020


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. G82343164

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 34,531,236
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 42,665,590
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    42,665,590
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.87%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. G82343164

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 34,531,236
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 42,665,590
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    42,665,590
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.87%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. G82343164

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 34,531,236
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 42,665,590
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    42,665,590
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.87%
    12. TYPE OF REPORTING PERSON

    HC

    Item 1.
    (a) Name of Issuer
    SMITH & NEPHEW PLC
    (b) Address of Issuer's Principal Executive Offices
    15 Adam Street
    London England, X0 WC2N 6LA
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    G82343164
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Exhibit A directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:

    Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    See attached Exhibit A.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021


    Exhibit A

    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.


    EXHIBIT B

    JOINT FILING AGREEMENT

    The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of SMITH & NEPHEW PLC is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.


    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    Get the next $SNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNN

    DatePrice TargetRatingAnalyst
    4/25/2025Buy → Hold
    HSBC Securities
    3/12/2025Buy → Neutral
    UBS
    11/6/2024Buy → Hold
    Berenberg
    11/1/2024Buy → Hold
    Deutsche Bank
    7/24/2024Buy
    Deutsche Bank
    6/5/2024Neutral → Buy
    UBS
    11/28/2023Underweight → Equal Weight
    Barclays
    11/3/2023Neutral → Overweight
    JP Morgan
    More analyst ratings

    $SNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cadence Welcomes Bob White to Board of Directors

      STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors.  Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM.  He recent

      9/12/24 10:57:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew's leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and

      5/14/25 8:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

      The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated:  Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 4-year period.1-3 **  Superior functional gains: Patients treated with the

      5/7/25 8:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

      HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB:AURX) ("Nuo"), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an exclusive private label distribution agreement ("Agreement") with global medical technology company Smith+Nephew ((LSE:SN, NYSE:SNN). Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo's underlying Aurix® System to the United States wound care market. Nuo will continue to be responsible for manufacturing the product.   The Aurix product

      4/29/25 4:30:00 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Smith & Nephew downgraded by HSBC Securities

      HSBC Securities downgraded Smith & Nephew from Buy to Hold

      4/25/25 8:30:48 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by UBS

      UBS downgraded Smith & Nephew from Buy to Neutral

      3/12/25 7:34:02 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by Berenberg

      Berenberg downgraded Smith & Nephew from Buy to Hold

      11/6/24 6:23:06 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: Plc Nephew & Smith claimed ownership of 5,428,680 units of Class A Common Stock and claimed ownership of 16,534,814 units of Class B Common Stock

      3 - SMITH & NEPHEW PLC (0000845982) (Reporting)

      2/12/21 6:00:30 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

      SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

      7/9/24 12:00:10 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)

      2/3/21 1:13:21 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    SEC Filings

    See more
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/21/25 10:40:08 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/14/25 8:13:22 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Smith & Nephew SNATS Inc.

      SD - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/9/25 11:07:04 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Financials

    Live finance-specific insights

    See more
    • Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research

      New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc

      3/3/25 8:20:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Wound Care Market Will Reach USD 31.81 Billion by 2030 on the Back of Growth in the North American Market

      New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra

      8/29/22 3:20:00 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

      Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an

      6/1/22 2:30:00 AM ET
      $SNN
      Industrial Specialties
      Health Care